Replicel
Collapse
X
-
-
You called me lonely ****** a while back.
Dude seriously i am not responsible that you are 22 years old with hair lossComment
-
Comment
-
You want everyone to be realistic, yet you are using "ten years away" as your reference point which is just as baseless of a prediction as everyone else's in this thread. Questioning things is fine, and this forum definitely needs to stay levelheaded, but at least provide some substance to back your claims rather than spouting out aimless cynicisms. The only thing worse than a balding loser is a balding loser who gets a kick out of riling everyone up.Comment
-
Comment
-
Yes I do. Nothing.
Nothing but pics of mice with hairy ears, no info on whether it is even slightly beneficial on humans, and talks of a fantasy fast release to market.
Ok I don't know for sure. But I'd put money on it.Comment
-
These people are research scientists, not genies.Comment
-
I've been watching this site for over 5 years and I've seen em come and go. I know that first of all Replicel need to prove safety and then that it actually works on humans. And then they start the real FDA process.
Also what pisses me off about these hollow interviews is that Replicel have never said whether it works on humans. All they have said is that things are going well. And I presume that what they mean is that they have administered it to humans and that those humans havent died. Well its a start.
I'm still pretty certain that Aderans and maybe Histogen will come to market first. If Replicel make it to market they will still make hundreds of millions of dollars.Comment
-
Exactly. People are like "WOW REPLICEL ARE GOING TO BE FIRST TO MARKET BECAUSE BLAH BLAH BLAH..."
I've been watching this site for over 5 years and I've seen em come and go. I know that first of all Replicel need to prove safety and then that it actually works on humans. And then they start the real FDA process.
Also what pisses me off about these hollow interviews is that Replicel have never said whether it works on humans. All they have said is that things are going well. And I presume that what they mean is that they have administered it to humans and that those humans havent died. Well its a start.
I'm still pretty certain that Aderans and maybe Histogen will come to market first. If Replicel make it to market they will still make hundreds of millions of dollars.
I personally am not going to predict with any type of certainty as to which treatment will come to market first. Some, and maybe even you, will say Aderans will first, based possibly on how far they are in the trials. But if its all about where a treatment is at in the trial phase, then it would make more sense to predict Follica will be the first to come to market as it has actually finished phase 2. Not saying that Follica will be the first to hit the market (if it even does), as again, at this point with all these possible treatments, there is no strong grounding as to predict which ones will come first.
The only guess I have about all this is that I think its likely that at the very least one of these treatments will be successful (saying none of them will work I think engaging in naive cynicism). But as to which will be successful or which will hit the market first is still too big of a question mark.Comment
-
Well, to be fair, they're limited by what they can say due to the shareholders, and this is true for all companies. And I don't think the interviews are hollow. Sure, we're not hearing what we all hope to hear (i.e. we definitely have a cure here), but its nice to know that they are keeping the balding community informed in some type of a way.
I personally am not going to predict with any type of certainty as to which treatment will come to market first. Some, and maybe even you, will say Aderans will first, based possibly on how far they are in the trials. But if its all about where a treatment is at in the trial phase, then it would make more sense to predict Follica will be the first to come to market as it has actually finished phase 2. Not saying that Follica will be the first to hit the market (if it even does), as again, at this point with all these possible treatments, there is no strong grounding as to predict which ones will come first.
The only guess I have about all this is that I think its likely that at the very least one of these treatments will be successful (saying none of them will work I think engaging in naive cynicism). But as to which will be successful or which will hit the market first is still too big of a question mark.
I don't give a roos poo if the Replicel CEO does a nice talk about how he's having a nice day and that he's feeling positive. I just want to know if it works. Or if it looks like its going to work. And to that end most of the interviews are hollow. At least to me. Spencer just asks the same feel good passing of the time questions and don't get us any closer to knowing. I heard the interview and felt hollow and empty afterwards - I felt exactly where I was before I heard the interview or worse.
I had forgotten about Follica. In my mind, the ones that have a product that delivers the results and gets through the FDA process first, will be the first to market. Its logical but like you kinda say it isnt guaranteed :PComment
-
Well, to be fair, they're limited by what they can say due to the shareholders, and this is true for all companies. And I don't think the interviews are hollow. Sure, we're not hearing what we all hope to hear (i.e. we definitely have a cure here), but its nice to know that they are keeping the balding community informed in some type of a way.
I personally am not going to predict with any type of certainty as to which treatment will come to market first. Some, and maybe even you, will say Aderans will first, based possibly on how far they are in the trials. But if its all about where a treatment is at in the trial phase, then it would make more sense to predict Follica will be the first to come to market as it has actually finished phase 2. Not saying that Follica will be the first to hit the market (if it even does), as again, at this point with all these possible treatments, there is no strong grounding as to predict which ones will come first.
The only guess I have about all this is that I think its likely that at the very least one of these treatments will be successful (saying none of them will work I think engaging in naive cynicism). But as to which will be successful or which will hit the market first is still too big of a question mark.Comment
-
Comment